RRC ID 83818
Author Mine H, Sugimoto K, Kobayashi M, Takagi H, Okabe N, Muto S, Kobayashi Y, Hashimoto Y, Suzuki H, Chiba H.
Title Abnormal phosphorylation of human LRH1 at Ser510 predicts poor prognosis and promotes cell viability in lung squamous cell carcinoma.
Journal BMC Cancer
Abstract The nuclear receptor liver receptor homolog 1 (LRH1)/NR5A2 is aberrantly expressed in diverse cancer types, including liver and lung cancers. Since we previously showed that excessive phosphorylation of human LRH1 at S510 (hLRH1pS510-high) is predictable of hepatocellular carcinoma recurrence, we here clarified the clinicopathological and biological significance of hLRH1pS510-high in lung cancer. By immunohistochemistry using an anti-hLRH1pS510 monoclonal antibody, we evaluated the hLRH1pS510 signals in 151 and 150 cases of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) tissues, respectively, and performed clinicopathological analysis. hLRH1pS510 was localized in the nucleus of tumor cells in LUAD and LUSC tissues with different intensity and proportions among the patients. Of note, the strong hLRH1pS510 signal was occasionally detectable in LUAD and LUSC cells at the expanding tumor edges. A semi-quantitative analysis revealed that 28 (18.4%) and 36 (24.0%) of LUAD and LUSC cases, respectively, exhibited hLRH1pS510-high. Kaplan-Meier plots showed significant differences in the disease-free survival (DFS) between the hLRH1pS510-high and hLRH1pS510-low groups in LUSC, but not in LUAD patients. hLRH1pS510-high was also significantly correlated with recurrence in LUSC patients. Additionally, by multivariate analysis, hLRH1pS510-high represented an independent biomarker for the DFS of LUSC patients. Furthermore, the impact of hLRH1pS510 on the viability of LUSC cells was evaluated by comparing phenotypes among two distinct LUSC cell lines expressing wild-type LRH1, LRH1S510A, and LRH1S510E. Consequently, we demonstrated that phosphorylation of hLRH1S510 accelerates the viability of LUSC cells. Thus, hLRH1pS510 is attractive not only as the predictive biomarker for LUSC but also as the potential therapeutic target.
Volume 25(1)
Pages 764
Published 2025-4-23
DOI 10.1186/s12885-025-14160-6
PII 10.1186/s12885-025-14160-6
PMID 40269773
PMC PMC12016208
MeSH Adult Aged Biomarkers, Tumor / metabolism Carcinoma, Squamous Cell* / genetics Carcinoma, Squamous Cell* / metabolism Carcinoma, Squamous Cell* / mortality Carcinoma, Squamous Cell* / pathology Cell Line, Tumor Cell Survival / genetics Female Humans Kaplan-Meier Estimate Lung Neoplasms* / genetics Lung Neoplasms* / metabolism Lung Neoplasms* / mortality Lung Neoplasms* / pathology Male Middle Aged Phosphorylation Prognosis Receptors, Cytoplasmic and Nuclear* / genetics Receptors, Cytoplasmic and Nuclear* / metabolism Serine / metabolism
IF 3.15
Resource
Human and Animal Cells RERF-LC-AI(RCB0444)